Characterizing therapeutic target antigen expression in anaplastic carcinoma of the ovary

Read full text Summarise with VIRAT
Authors: Mackenzie W. Sullivan, Michael Herman Chui, Alexa N. Kanbergs, Hunter Green, Kaitlyn Y. Gill, Pier Selenica, Achim A. Jungbluth, Kara C. Long, Yukio Sonoda, Jennifer Jean Mueller, Christopher M. Tarney, Rachel Nicole Grisham
+4 more Vicky Makker, Nadeem R. Abu‐Rustum, Britta Weigelt, Roisin Eilish O'Cearbhaill
Cited by: 0
References: 14

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Objective: Novel treatment strategies are needed for patients with anaplastic carcinoma of the ovary given the high incidence of chemoresistance to conventional systemic therapies. Here we sought to evaluate HER2, FOLR1, TROP2, and mismatch repair protein expression as well as the tumor mutational burden of anaplastic carcinoma of the ovary. Methods: We retrospectively identified a total of 9 anaplastic ovarian carcinomas in institutional databases from 2013 to 2023, including one case from a collaborating institution. Cases with adequate tissue available underwent immunohistochemical analysis for HER2, FOLR1, TROP2, and mismatch repair proteins MLH1, MSH2, MSH6, and PMS2. Tumor mutational burden was obtained from tumor-normal panel sequencing. Results: Anaplastic carcinoma of the ovary demonstrated low or absent expression of FOLR1, HER2, and TROP2 protein. FOLR1 expression in the two cases was weak and below currently used clinical cutoffs for mirvetuximab soravtansine eligibility. HER2 expression was low in the two anaplastic carcinomas (1-2+). TROP2 expression was low in one case (H-score of 60) and negative in the other five. All cases were mismatch repair proficient by immunohistochemistry and had low tumor mutational burden (median, 3.3 mut/Mb; range, 0.8-6.9). Conclusion: Only a subset of anaplastic carcinomas of the ovary express targetable tumor antigens at low levels, suggesting that these may have limited benefit from antibody-drug conjugates. Likewise, due to mismatch repair proficiency and low tumor mutational burden, immunotherapy is unlikely to be effective in this rare disease.

Fields of Study & Subjects

Ovarian cancer diagnosis and treatment BRCA gene mutations in cancer Cancer Immunotherapy and Biomarkers

Publication details

Journal / source
Gynecologic Oncology Reports
Volume
64
Pages
102064–102064
Publication date
26 March 2026
Language
EN